Agenus to Present Data on Neoantigen Vaccines and anti-CD137 Antibody at SITC 2018

Author's Avatar
Nov 07, 2018
Article's Main Image

- AutoSynVax™ (ASV™), AGEN2003 clinical trials data

- Novel targets in colorectal carcinoma (CRC) for off-the-shelf vaccine with pan indication development potential

- AGEN2373, a novel, potential best-in-class anti-CD137 antibody for the treatment of human malignancies, is well-tolerated in pre-clinical studies

PR Newswire